Pharmacoeconomics Aspects of Antiepileptic Drugs in Pediatric Patients with Epilepsy

Dorota Kopciuch, Jędrzej Fliciński, Barbara Steinborn, Anna Winczewska-Wiktor, Anna Paczkowska, Tomasz Zaprutko, Piotr Ratajczak, Elżbieta Nowakowska and Krzysztof Kus
Additional contact information
Dorota Kopciuch: Department of Pharmacoeconomics and Social Pharmacy, Karol Marcinkowski University of Medical Sciences in Poznań, 60-865 Poznan, Poland
Jędrzej Fliciński: Department of Developmental Neurology, Karol Marcinkowski University of Medical Sciences in Poznań, 60-355 Poznan, Poland
Barbara Steinborn: Department of Developmental Neurology, Karol Marcinkowski University of Medical Sciences in Poznań, 60-355 Poznan, Poland
Anna Winczewska-Wiktor: Department of Developmental Neurology, Karol Marcinkowski University of Medical Sciences in Poznań, 60-355 Poznan, Poland
Anna Paczkowska: Department of Pharmacoeconomics and Social Pharmacy, Karol Marcinkowski University of Medical Sciences in Poznań, 60-865 Poznan, Poland
Tomasz Zaprutko: Department of Pharmacoeconomics and Social Pharmacy, Karol Marcinkowski University of Medical Sciences in Poznań, 60-865 Poznan, Poland
Piotr Ratajczak: Department of Pharmacoeconomics and Social Pharmacy, Karol Marcinkowski University of Medical Sciences in Poznań, 60-865 Poznan, Poland
Elżbieta Nowakowska: Department of Pharmacology and Toxicology Institute of Health Sciences, Collegium Medicum, University of Zielona Gora, 65-417 Zielona Góra, Poland
Krzysztof Kus: Department of Pharmacoeconomics and Social Pharmacy, Karol Marcinkowski University of Medical Sciences in Poznań, 60-865 Poznan, Poland

IJERPH, 2022, vol. 19, issue 12, 1-8

Abstract: Objective: This study assessed the differentiation of treatment costs with newer and older antiepileptic drugs (AEDs) through its correlation with treatment effectiveness and an adverse event (AE) in pediatric patients with epilepsy (PPE). Methods: PPE on monotherapy of AEDs for the last 6 months were screened for this study. Seizure frequency during the study was compared with that within 6 months before the study. The following parameters were also assessed: quality of life in epilepsy, Pittsburgh Sleep Quality Index, and Liverpool AEs Profile. An incremental cost-effectiveness ratio (ICER) analysis based on the costs of pharmacotherapy was also performed. Results: Out of 80 PPE, 67 completed the study, and 13 PPE were lost after failing to meet the inclusion criteria. A total of 56.71% of PPE were on newer AEDs, and 43.28% were on older AEDs. Newer and older AEDs did not differ significantly in seizure frequency reduction and quality of life parameters, although these were improved significantly during the study period. As per ICER, newer AEDs need an additional EUR 36.82 per unit reduction in seizure frequency. Conclusion: Newer AEDs have comparatively better efficacy, although not significantly better than older AEDs. However, the additional cost per unit improvement is quite high with newer AEDs, necessitating pharmacoeconomic consideration in pediatric epilepsy treatment.

Keywords: antiepileptic drugs; children; epilepsy; pediatric patients with epilepsy; pharmacoeconomics; cost of pharmacotherapy; quality of life (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2022
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/19/12/7517/pdf (application/pdf)
https://www.mdpi.com/1660-4601/19/12/7517/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:19:y:2022:i:12:p:7517-:d:842813

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().